{"transactions":[{"id":1427180,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":41745,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":41745,"derivative":{"exercise_price":3.56,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":41745},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427179,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":68080,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":68080,"derivative":{"exercise_price":3.56,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":68080},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427178,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":94871,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":94871,"derivative":{"exercise_price":3.56,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":94871},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427177,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":9635,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023."}],"balance_after":9635,"derivative":{"exercise_price":3.56,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":9635},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427176,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":102564,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on February 22, 2023, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":102564,"derivative":{"exercise_price":3.56,"expiration_date":"2032-02-23","underlying":"Common Stock","underlying_shares":102564},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427175,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41745,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":41745},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427174,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":68080,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":68080},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427173,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":94871,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":94871},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427172,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9635,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2032-12-12","underlying":"Common Stock","underlying_shares":9635},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1427171,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:06:01.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":102564,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on February 22, 2023, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2032-02-23","underlying":"Common Stock","underlying_shares":102564},"source":{"system":"sec-edgar","filing":"0000950170-24-099299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024099299/ownership.xml","form_type":"4"}},{"id":1557385,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-03-29T16:30:13.000Z","date":"2024-03-27","kind":"grant","planned":false,"acquired":true,"shares":41745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":41745,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":41745},"source":{"system":"sec-edgar","filing":"0000950170-24-038700","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1766477/000095017024038700/ownership.xml","form_type":"4"}},{"id":2848661,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-18T17:06:49.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":19559,"price":25.29,"value":494647.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan on September 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold in multiple transactions at prices ranging from $25.00 to $25.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":215150,"source":{"system":"sec-edgar","filing":"0001739614-21-000039","document":"wf-form4_161368598906751.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1739614/000173961421000039/wf-form4_161368598906751.xml","form_type":"4"}},{"id":2848660,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-18T17:06:49.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":156474,"price":24.32,"value":3805447.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan on September 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $22.14 to $32.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":234709,"source":{"system":"sec-edgar","filing":"0001739614-21-000039","document":"wf-form4_161368598906751.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739614/000173961421000039/wf-form4_161368598906751.xml","form_type":"4"}},{"id":2903806,"issuer":{"id":90351,"kind":"organization","name":"Inhibrx, Inc.","symbol":"INBX"},"owners":[{"id":88173,"kind":"person","name":"Wagner Klaus W.","position":1,"cik":"0001766477","reported_name":"Wagner Klaus W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-19T16:14:55.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(1) Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter."}],"balance_after":120000,"derivative":{"exercise_price":33.63,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001739614-21-000020","document":"wf-form4_161109088199604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739614/000173961421000020/wf-form4_161109088199604.xml","form_type":"4"}}]}